<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="35581">Indole</z:chebi> <z:chebi fb="0" ids="16891">oxoacetic acid</z:chebi> derivatives were prepared and evaluated for in vitro binding to and inactivation of human plasminogen activator inhibitor-1 (PAI-1) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SAR</z:e> based on biochemical, physiological, and pharmacokinetic attributes led to identification of tiplaxtinin as the optimal selective PAI-1 inhibitor </plain></SENT>
<SENT sid="2" pm="."><plain>Tiplaxtinin exhibited in vivo oral efficacy in two different models of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The remarkable preclinical safety and metabolic stability profiles of tiplaxtinin led to advancing the compound to clinical trials </plain></SENT>
</text></document>